Lacktman Comments on Proposed Telemedicine Regulations in Washington, D.C.
October 10, 2017
mHealth Intelligence
Partner Nathaniel Lacktman is quoted in a mHealth Intelligence article, “Telehealth in the Nation’s Capital: DC Board Mulls Regulations,” about proposed telemedicine legislation in the District of Columbia that would enable health care providers to establish a doctor-patient relationship there as long as they first get the patient’s permission to use the technology.
Lacktman said the latest draft of the proposed regulations clarifies the definition of telemedicine and revises the modality required to create a valid physician-patient relationship. He also said it tweaks the definition of real-time to mean a system in which information is provided in such a way as to allow near immediate feedback. The previous draft defined real-time as “simultaneously or quickly enough to allow two or more individuals to communicate,” he said.
Lacktman said the latest draft of the proposed regulations clarifies the definition of telemedicine and revises the modality required to create a valid physician-patient relationship. He also said it tweaks the definition of real-time to mean a system in which information is provided in such a way as to allow near immediate feedback. The previous draft defined real-time as “simultaneously or quickly enough to allow two or more individuals to communicate,” he said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."